<p>Dyne Therapeutics（纳斯达克代码：DYN - 获取免费报告）于周一发布了其财报。该公司报告本季度每股收益为（$0.73），超出分析师一致预期的（$0.74）$0.01，RTT News 报道。在去年同期，该公司每股收益为（$1.05）。</p>
<p>获取 <strong>Dyne Therapeutics</strong> 的提醒：</p>
<h2>Dyne Therapeutics 股票表现</h2>
<p>周一交易时段，Dyne Therapeutics 股票上涨 $0.61，达到 $18.22。该股票成交量为 336,444 股，而其平均成交量为 2,062,577 股。该公司的债务与股本比率为 0.15，流动比率为 22.25，速动比率为 22.25。该公司的 50 日移动平均价格为$18.05，200 日移动平均价格为$18.59。该股票的市值为 30.1 亿美元，市盈率为-5.15，贝塔值为 1.08。Dyne Therapeutics 的 1 年最低价为$8.06，1 年最高价为$25.00。</p>
<h2>分析师评级变动</h2>
<p>DYN 曾受到多家研究分析师的关注。Chardan Capital 在 3 月 9 日的研究报告中重申了对 Dyne Therapeutics 的 “买入” 评级，并设定了$38.00 的目标价。Wall Street Zen 在 5 月 2 日的研究报告中将 Dyne Therapeutics 的评级从 “卖出” 下调至 “强烈卖出”。HC Wainwright 在 3 月 3 日的研究报告中将 Dyne Therapeutics 的目标价从$60.00 下调至$50.00，并给予该公司 “买入” 评级。摩根士丹利在 3 月 2 日的研究报告中将 Dyne Therapeutics 的目标价从$50.00 下调至$47.00，并给予该公司 “增持” 评级。最后，摩根大通在 1 月 20 日的研究报告中将 Dyne Therapeutics 的目标价从$17.00 下调至$16.00，并给予该公司 “中性” 评级。三位投资分析师对该股票给予了 “强烈买入” 评级，十一位给予了 “买入” 评级，两位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，共识目标价为$35.14。</p>
<p><strong>获取我们对 Dyne Therapeutics 的最新股票分析</strong></p>
<h2>内部人士下注</h2>
<p>在其他 Dyne Therapeutics 的新闻中，董事 Jason P. Rhodes 于 5 月 6 日出售了 83,219 股该公司的股票。该股票以平均价格$18.18 出售，总交易额为$1,512,921.42。出售后，该董事在公司持有 7,962 股，价值约$144,749.16。此次交易使其持股减少了 91.27%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过 SEC 网站访问。该交易是在预先安排的 10b5-1 交易计划下执行的。在上个季度，内部人士出售了价值$29,694,469 的 1,552,911 股公司股票。目前，内部人士持有该公司 20.77% 的股票。</p>
<h2>Dyne Therapeutics 的机构交易</h2>
<p>多家对冲基金最近调整了对 DYN 的持股。T. Rowe Price Investment Management Inc.在第四季度将其在 Dyne Therapeutics 的持股增加了 523.7%。T. Rowe Price Investment Management Inc.现在拥有 17,540,089 股该公司的股票，价值$343,085,000，在此期间又购买了 14,727,667 股。Orbis Allan Gray Ltd 在第四季度获得了 Dyne Therapeutics 的新头寸，价值约$93,926,000。Adage Capital Partners GP L.L.C.在第二季度获得了 Dyne Therapeutics 的新头寸，价值约$30,378,000。Marshall Wace LLP 在第三季度将其在 Dyne Therapeutics 的持股增加了 572.9%。Marshall Wace LLP 现在拥有 3,013,377 股该公司的股票，价值$38,119,000，在此期间又购买了 2,565,570 股。最后，Vestal Point Capital LP 在第三季度将其在 Dyne Therapeutics 的持股增加了 281.4%。Vestal Point Capital LP 现在拥有 2,775,000 股该公司的股票，价值$35,104,000，在此期间又购买了 2,047,500 股。对冲基金和其他机构投资者持有该公司 96.68% 的股票。</p>
<h2>关于 Dyne Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Dyne Therapeutics 是一家临床阶段的生物技术公司，专注于开发针对严重罕见疾病的局部基因调控疗法。该公司的专有 FORCE（促进的正交受体介导的货物评估）平台旨在实现寡核苷酸和基因疗法模式的靶向递送，主要针对骨骼和呼吸肌肉。Dyne 的主要项目集中在杜氏肌营养不良症（DMD）、肌强直性营养不良症 1 型（DM1）和面肩肱肌营养不良症（FSHD），目前正在进行安全性、耐受性和组织特异性的临床前和早期临床研究。</p>
<p>自 2019 年由 Flagship Pioneering 创立以来，Dyne 已经通过其模块化递送方法推进了多个产品候选者，该方法将工程化配体与治疗性载荷结合，以改善肌肉细胞的摄取。</p>
<h2>阅读更多</h2>
<ul>
<li>我们更看好的五只股票，胜过 Dyne Therapeutics</li>
<li>AI 股息增加：3 只巨头提升分红</li>
<li>疯狂的周一：这家 SaaS 领军者的反弹只是个开始</li>
<li>5 只有望受益于 AI 推理热潮的股票</li>
<li>Meta Platforms 的财报后剧烈波动：分析师的目标价现状</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFlO?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFlO"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Dyne Therapeutics 吗？</h2>
<p>在考虑 Dyne Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Dyne Therapeutics 并不在名单上。</p>
<p>虽然 Dyne Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

基因改革 ETF - ARK

医疗业 ETF - Vanguard

纳斯达克生物科技指数 ETF - iShares Nasdaq

医疗业 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

生物科技 ETF - VanEck Vectors

标普生物技术 ETF - SPDR

<p>Dyne Therapeutics（纳斯达克代码：DYN）公布了季度财报，报告每股收益（EPS）为（$0.73），超过了预期的（$0.74）。与去年同期的每股收益（$1.05）相比有所改善。股价上涨至$18.22，市值为$30.1 亿。分析师的评级意见不一，普遍评级为 “适度买入”，目标价为$35.14。内部人士最近出售了大量股份，机构投资者持有 96.68% 的股份。Dyne 专注于针对罕见疾病的基因调控疗法，包括杜氏肌营养不良症</p>

<p>Dyne Therapeutics (NASDAQ:DYN - Get Free Report) issued its earnings results on Monday. The company reported ($0.73) earnings per share for the quarter, beating analysts' consensus estimates of ($0.74) by $0.01, RTT News reports. During the same period in the prior year, the business earned ($1.05) EPS.</p>
<div class="lb-trans"><p>Dyne Therapeutics（纳斯达克代码：DYN - 获取免费报告）于周一发布了其财报。该公司报告本季度每股收益为（$0.73），超出分析师一致预期的（$0.74）$0.01，RTT News 报道。在去年同期，该公司每股收益为（$1.05）。</p>
</div><p>Get <strong>Dyne Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Dyne Therapeutics</strong> 的提醒：</p>
</div><h2>Dyne Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Dyne Therapeutics 股票表现</h2>
</div><p>Dyne Therapeutics stock traded up $0.61 during trading hours on Monday, hitting $18.22. 336,444 shares of the stock traded hands, compared to its average volume of 2,062,577. The company has a debt-to-equity ratio of 0.15, a current ratio of 22.25 and a quick ratio of 22.25. The firm's 50 day moving average price is $18.05 and its 200-day moving average price is $18.59. The stock has a market capitalization of $3.01 billion, a price-to-earnings ratio of -5.15 and a beta of 1.08. Dyne Therapeutics has a 1 year low of $8.06 and a 1 year high of $25.00.</p>
<div class="lb-trans"><p>周一交易时段，Dyne Therapeutics 股票上涨 $0.61，达到 $18.22。该股票成交量为 336,444 股，而其平均成交量为 2,062,577 股。该公司的债务与股本比率为 0.15，流动比率为 22.25，速动比率为 22.25。该公司的 50 日移动平均价格为$18.05，200 日移动平均价格为$18.59。该股票的市值为 30.1 亿美元，市盈率为-5.15，贝塔值为 1.08。Dyne Therapeutics 的 1 年最低价为$8.06，1 年最高价为$25.00。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>DYN has been the subject of a number of research analyst reports. Chardan Capital reaffirmed a &#34;buy&#34; rating and set a $38.00 target price on shares of Dyne Therapeutics in a research report on Monday, March 9th. Wall Street Zen lowered Dyne Therapeutics from a &#34;sell&#34; rating to a &#34;strong sell&#34; rating in a research report on Saturday, May 2nd. HC Wainwright decreased their target price on Dyne Therapeutics from $60.00 to $50.00 and set a &#34;buy&#34; rating for the company in a research report on Tuesday, March 3rd. Morgan Stanley decreased their target price on Dyne Therapeutics from $50.00 to $47.00 and set an &#34;overweight&#34; rating for the company in a research report on Monday, March 2nd. Finally, JPMorgan Chase &amp; Co. decreased their target price on Dyne Therapeutics from $17.00 to $16.00 and set a &#34;neutral&#34; rating for the company in a research report on Tuesday, January 20th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $35.14.</p>
<div class="lb-trans"><p>DYN 曾受到多家研究分析师的关注。Chardan Capital 在 3 月 9 日的研究报告中重申了对 Dyne Therapeutics 的 “买入” 评级，并设定了$38.00 的目标价。Wall Street Zen 在 5 月 2 日的研究报告中将 Dyne Therapeutics 的评级从 “卖出” 下调至 “强烈卖出”。HC Wainwright 在 3 月 3 日的研究报告中将 Dyne Therapeutics 的目标价从$60.00 下调至$50.00，并给予该公司 “买入” 评级。摩根士丹利在 3 月 2 日的研究报告中将 Dyne Therapeutics 的目标价从$50.00 下调至$47.00，并给予该公司 “增持” 评级。最后，摩根大通在 1 月 20 日的研究报告中将 Dyne Therapeutics 的目标价从$17.00 下调至$16.00，并给予该公司 “中性” 评级。三位投资分析师对该股票给予了 “强烈买入” 评级，十一位给予了 “买入” 评级，两位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，共识目标价为$35.14。</p>
</div><p><strong>Get Our Latest Stock Analysis on Dyne Therapeutics</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Dyne Therapeutics 的最新股票分析</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other Dyne Therapeutics news, Director Jason P. Rhodes sold 83,219 shares of the business's stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $18.18, for a total transaction of $1,512,921.42. Following the sale, the director owned 7,962 shares in the company, valued at approximately $144,749.16. The trade was a 91.27% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 1,552,911 shares of company stock worth $29,694,469. 20.77% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他 Dyne Therapeutics 的新闻中，董事 Jason P. Rhodes 于 5 月 6 日出售了 83,219 股该公司的股票。该股票以平均价格$18.18 出售，总交易额为$1,512,921.42。出售后，该董事在公司持有 7,962 股，价值约$144,749.16。此次交易使其持股减少了 91.27%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过 SEC 网站访问。该交易是在预先安排的 10b5-1 交易计划下执行的。在上个季度，内部人士出售了价值$29,694,469 的 1,552,911 股公司股票。目前，内部人士持有该公司 20.77% 的股票。</p>
</div><h2>Institutional Trading of Dyne Therapeutics</h2>
<div class="lb-trans"><h2>Dyne Therapeutics 的机构交易</h2>
</div><p>A number of hedge funds have recently modified their holdings of DYN. T. Rowe Price Investment Management Inc. raised its holdings in Dyne Therapeutics by 523.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company's stock worth $343,085,000 after purchasing an additional 14,727,667 shares during the period. Orbis Allan Gray Ltd acquired a new position in Dyne Therapeutics in the 4th quarter worth about $93,926,000. Adage Capital Partners GP L.L.C. acquired a new position in Dyne Therapeutics in the 2nd quarter worth about $30,378,000. Marshall Wace LLP raised its holdings in Dyne Therapeutics by 572.9% in the 3rd quarter. Marshall Wace LLP now owns 3,013,377 shares of the company's stock worth $38,119,000 after purchasing an additional 2,565,570 shares during the period. Finally, Vestal Point Capital LP raised its holdings in Dyne Therapeutics by 281.4% in the 3rd quarter. Vestal Point Capital LP now owns 2,775,000 shares of the company's stock worth $35,104,000 after purchasing an additional 2,047,500 shares during the period. Hedge funds and other institutional investors own 96.68% of the company's stock.</p>
<div class="lb-trans"><p>多家对冲基金最近调整了对 DYN 的持股。T. Rowe Price Investment Management Inc.在第四季度将其在 Dyne Therapeutics 的持股增加了 523.7%。T. Rowe Price Investment Management Inc.现在拥有 17,540,089 股该公司的股票，价值$343,085,000，在此期间又购买了 14,727,667 股。Orbis Allan Gray Ltd 在第四季度获得了 Dyne Therapeutics 的新头寸，价值约$93,926,000。Adage Capital Partners GP L.L.C.在第二季度获得了 Dyne Therapeutics 的新头寸，价值约$30,378,000。Marshall Wace LLP 在第三季度将其在 Dyne Therapeutics 的持股增加了 572.9%。Marshall Wace LLP 现在拥有 3,013,377 股该公司的股票，价值$38,119,000，在此期间又购买了 2,565,570 股。最后，Vestal Point Capital LP 在第三季度将其在 Dyne Therapeutics 的持股增加了 281.4%。Vestal Point Capital LP 现在拥有 2,775,000 股该公司的股票，价值$35,104,000，在此期间又购买了 2,047,500 股。对冲基金和其他机构投资者持有该公司 96.68% 的股票。</p>
</div><h2>About Dyne Therapeutics</h2>
<div class="lb-trans"><h2>关于 Dyne Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.</p>
<div class="lb-trans"><p>Dyne Therapeutics 是一家临床阶段的生物技术公司，专注于开发针对严重罕见疾病的局部基因调控疗法。该公司的专有 FORCE（促进的正交受体介导的货物评估）平台旨在实现寡核苷酸和基因疗法模式的靶向递送，主要针对骨骼和呼吸肌肉。Dyne 的主要项目集中在杜氏肌营养不良症（DMD）、肌强直性营养不良症 1 型（DM1）和面肩肱肌营养不良症（FSHD），目前正在进行安全性、耐受性和组织特异性的临床前和早期临床研究。</p>
</div><p>Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.</p>
<div class="lb-trans"><p>自 2019 年由 Flagship Pioneering 创立以来，Dyne 已经通过其模块化递送方法推进了多个产品候选者，该方法将工程化配体与治疗性载荷结合，以改善肌肉细胞的摄取。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than Dyne Therapeutics</li>
<li>AI Dividend Increases: 3 Massive Winners Boosting Payouts</li>
<li>Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader</li>
<li>5 Stocks Positioned to Benefit From the AI Inference Boom</li>
<li>Meta Platforms’ Wild Post-Earnings Swings: Where Analyst Price Targets Stand Now</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Dyne Therapeutics</li>
<li>AI 股息增加：3 只巨头提升分红</li>
<li>疯狂的周一：这家 SaaS 领军者的反弹只是个开始</li>
<li>5 只有望受益于 AI 推理热潮的股票</li>
<li>Meta Platforms 的财报后剧烈波动：分析师的目标价现状</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFlO" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=DYN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Dyne Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Dyne Therapeutics 吗？</h2>
</div><p>Before you consider Dyne Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Dyne Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Dyne Therapeutics 并不在名单上。</p>
</div><p>While Dyne Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Dyne Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Dyne Therapeutics (NASDAQ:DYN) Announces Earnings Results

Market Beat

Dyne Therapeutics

摩根士丹利

摩根大通

普信金融

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Dyne Therapeutics (NASDAQ:DYN) 公布了财务业绩